FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2893363084> ?p ?o ?g. }

• W2893363084 endingPage "73" @default.
• W2893363084 startingPage "63" @default.
• W2893363084 abstract "Background Obesity is a major challenge for people with schizophrenia. Aims We assessed whether STEPWISE, a theory-based, group structured lifestyle education programme could support weight reduction in people with schizophrenia. Method In this randomised controlled trial (study registration: ISRCTN19447796), we recruited adults with schizophrenia, schizoaffective disorder or first-episode psychosis from ten mental health organisations in England. Participants were randomly allocated to the STEPWISE intervention or treatment as usual. The 12-month intervention comprised four 2.5 h weekly group sessions, followed by 2-weekly maintenance contact and group sessions at 4, 7 and 10 months. The primary outcome was weight change after 12 months. Key secondary outcomes included diet, physical activity, biomedical measures and patient-related outcome measures. Cost-effectiveness was assessed and a mixed-methods process evaluation was included. Results Between 10 March 2015 and 31 March 2016, we recruited 414 people (intervention 208, usual care 206) with 341 (84.4%) participants completing the trial. At 12 months, weight reduction did not differ between groups (mean difference 0.0 kg, 95% CI −1.6 to 1.7, P = 0.963); physical activity, dietary intake and biochemical measures were unchanged. STEPWISE was well-received by participants and facilitators. The healthcare perspective incremental cost-effectiveness ratio was £246 921 per quality-adjusted life-year gained. Conclusions Participants were successfully recruited and retained, indicating a strong interest in weight interventions; however, the STEPWISE intervention was neither clinically nor cost-effective. Further research is needed to determine how to manage overweight and obesity in people with schizophrenia. Declaration of interest R.I.G.H. received fees for lecturing, consultancy work and attendance at conferences from the following: Boehringer Ingelheim, Eli Lilly, Janssen, Lundbeck, Novo Nordisk, Novartis, Otsuka, Sanofi, Sunovion, Takeda, MSD. M.J.D. reports personal fees from Novo Nordisk, Sanofi-Aventis, Lilly, Merck Sharp & Dohme, Boehringer Ingelheim, AstraZeneca, Janssen, Servier, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceuticals International Inc.; and, grants from Novo Nordisk, Sanofi-Aventis, Lilly, Boehringer Ingelheim, Janssen. K.K. has received fees for consultancy and speaker for Novartis, Novo Nordisk, Sanofi-Aventis, Lilly, Servier and Merck Sharp & Dohme. He has received grants in support of investigator and investigator-initiated trials from Novartis, Novo Nordisk, Sanofi-Aventis, Lilly, Pfizer, Boehringer Ingelheim and Merck Sharp & Dohme. K.K. has received funds for research, honoraria for speaking at meetings and has served on advisory boards for Lilly, Sanofi-Aventis, Merck Sharp & Dohme and Novo Nordisk. D.Sh. is expert advisor to the NICE Centre for guidelines; board member of the National Collaborating Centre for Mental Health (NCCMH); clinical advisor (paid consultancy basis) to National Clinical Audit of Psychosis (NCAP); views are personal and not those of NICE, NCCMH or NCAP. J.P. received personal fees for involvement in the study from a National Institute for Health Research (NIHR) grant. M.E.C. and Y.D. report grants from NIHR Health Technology Assessment, during the conduct of the study; and The Leicester Diabetes Centre, an organisation (employer) jointly hosted by an NHS Hospital Trust and the University of Leicester and who is holder (through the University of Leicester) of the copyright of the STEPWISE programme and of the DESMOND suite of programmes, training and intervention fidelity framework that were used in this study. S.R. has received honorarium from Lundbeck for lecturing. F.G. reports personal fees from Otsuka and Lundbeck, personal fees and non-financial support from Sunovion, outside the submitted work; and has a family member with professional links to Lilly and GSK, including shares. F.G. is in part funded by the National Institute for Health Research Collaboration for Leadership in Applied Health Research & Care Funding scheme, by the Maudsley Charity and by the Stanley Medical Research Institute and is supported by the by the Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London." @default.
• W2893363084 created "2018-10-05" @default.
• W2893363084 creator A5019428645 @default.
• W2893363084 creator A5026289941 @default.
• W2893363084 creator A5027143609 @default.
• W2893363084 creator A5028224373 @default.
• W2893363084 creator A5032233929 @default.
• W2893363084 creator A5037220433 @default.
• W2893363084 creator A5037914642 @default.
• W2893363084 creator A5043675763 @default.
• W2893363084 creator A5045470491 @default.
• W2893363084 creator A5047426107 @default.
• W2893363084 creator A5047473346 @default.
• W2893363084 creator A5051427747 @default.
• W2893363084 creator A5052661425 @default.
• W2893363084 creator A5057222972 @default.
• W2893363084 creator A5058014295 @default.
• W2893363084 creator A5058139106 @default.
• W2893363084 creator A5062699494 @default.
• W2893363084 creator A5065743025 @default.
• W2893363084 creator A5067547893 @default.
• W2893363084 creator A5070656741 @default.
• W2893363084 creator A5070911163 @default.
• W2893363084 creator A5074884532 @default.
• W2893363084 creator A5078298515 @default.
• W2893363084 creator A5082544212 @default.
• W2893363084 creator A5083222970 @default.
• W2893363084 creator A5084593004 @default.
• W2893363084 creator A5089101237 @default.
• W2893363084 date "2018-09-25" @default.
• W2893363084 modified "2023-10-10" @default.
• W2893363084 title "Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis (STEPWISE): randomised controlled trial" @default.
• W2893363084 cites W1968434622 @default.
• W2893363084 cites W1989488925 @default.
• W2893363084 cites W1990166011 @default.
• W2893363084 cites W1999270670 @default.
• W2893363084 cites W2010135111 @default.
• W2893363084 cites W2020844317 @default.
• W2893363084 cites W2030894553 @default.
• W2893363084 cites W2050555449 @default.
• W2893363084 cites W2050986291 @default.
• W2893363084 cites W2089476063 @default.
• W2893363084 cites W2111224842 @default.
• W2893363084 cites W2132322340 @default.
• W2893363084 cites W2136012322 @default.
• W2893363084 cites W2147474481 @default.
• W2893363084 cites W2148835133 @default.
• W2893363084 cites W2202989893 @default.
• W2893363084 cites W2347099014 @default.
• W2893363084 cites W2471447259 @default.
• W2893363084 cites W2510382992 @default.
• W2893363084 cites W2527328081 @default.
• W2893363084 cites W2558794426 @default.
• W2893363084 cites W2604907288 @default.
• W2893363084 cites W2753377439 @default.
• W2893363084 cites W2784448919 @default.
• W2893363084 cites W4292806894 @default.
• W2893363084 doi "https://doi.org/10.1192/bjp.2018.167" @default.
• W2893363084 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6330076" @default.
• W2893363084 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30251622" @default.
• W2893363084 hasPublicationYear "2018" @default.
• W2893363084 type Work @default.
• W2893363084 sameAs 2893363084 @default.
• W2893363084 citedByCount "67" @default.
• W2893363084 countsByYear W28933630842018 @default.
• W2893363084 countsByYear W28933630842019 @default.
• W2893363084 countsByYear W28933630842020 @default.
• W2893363084 countsByYear W28933630842021 @default.
• W2893363084 countsByYear W28933630842022 @default.
• W2893363084 countsByYear W28933630842023 @default.
• W2893363084 crossrefType "journal-article" @default.
• W2893363084 hasAuthorship W2893363084A5019428645 @default.
• W2893363084 hasAuthorship W2893363084A5026289941 @default.
• W2893363084 hasAuthorship W2893363084A5027143609 @default.
• W2893363084 hasAuthorship W2893363084A5028224373 @default.
• W2893363084 hasAuthorship W2893363084A5032233929 @default.
• W2893363084 hasAuthorship W2893363084A5037220433 @default.
• W2893363084 hasAuthorship W2893363084A5037914642 @default.
• W2893363084 hasAuthorship W2893363084A5043675763 @default.
• W2893363084 hasAuthorship W2893363084A5045470491 @default.
• W2893363084 hasAuthorship W2893363084A5047426107 @default.
• W2893363084 hasAuthorship W2893363084A5047473346 @default.
• W2893363084 hasAuthorship W2893363084A5051427747 @default.
• W2893363084 hasAuthorship W2893363084A5052661425 @default.
• W2893363084 hasAuthorship W2893363084A5057222972 @default.
• W2893363084 hasAuthorship W2893363084A5058014295 @default.
• W2893363084 hasAuthorship W2893363084A5058139106 @default.
• W2893363084 hasAuthorship W2893363084A5062699494 @default.
• W2893363084 hasAuthorship W2893363084A5065743025 @default.
• W2893363084 hasAuthorship W2893363084A5067547893 @default.
• W2893363084 hasAuthorship W2893363084A5070656741 @default.
• W2893363084 hasAuthorship W2893363084A5070911163 @default.
• W2893363084 hasAuthorship W2893363084A5074884532 @default.
• W2893363084 hasAuthorship W2893363084A5078298515 @default.
• W2893363084 hasAuthorship W2893363084A5082544212 @default.
• W2893363084 hasAuthorship W2893363084A5083222970 @default.
• W2893363084 hasAuthorship W2893363084A5084593004 @default.
• W2893363084 hasAuthorship W2893363084A5089101237 @default.

• next